BioSpace News Archive

Vial has announced that the VialConnect interface with ModMed® is now live. With VialConnect, research clinics that use ModMed’s EHR EMA® can seamlessly filter their patient databases to streamline clinical trial study recruitment for free.

Sciwind Biosciences Co., Ltd., a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapies to treat metabolic disease, today announced positive interim topline results from a 26-week Phase 1c/2a clinical trial of XW003 (Ecnoglutide) in overweight or obese Chinese adult volunteers.

Ainos, Inc., a diversified medtech company focused on the development of novel point-of-care testing, low-dose interferon therapeutics, and synthetic RNA-driven preventative medicine, announced the pricing of its underwritten public offering of 780,000 units at a public offering price of $4.25 per unit.

Zealand Pharma Announces Voluntary Delisting of American DepositaryShares from the U.S.-Based Nasdaq Global Select Market

Akoya Biosciences, Inc., The Spatial Biology Company®, announced its financial results for the second quarter ending June 30, 2022.

Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported financial results for the second quarter ended June 30, 2022 and provided a corporate update.

– RxSight, Inc., an ophthalmic medical device company dedicated to improving the vision of patients following cataract surgery, reported financial results for the three and six months ended June 30, 2022.

Calithera Biosciences, Inc., a clinical-stage, precision-oncology biopharmaceutical company, announced Company’s second quarter 2022 financial results will be released on Monday, August 15, 2022.

MediWound Ltd. announced the appointments of Mr. Nachum Shamir as the Chairman of the Company’s Board of Directors and Dr. Robert Snyder as the Company’s Chief Medical Officer.

23andMe Holding Co., a leading consumer genetics and research company with a mission to help people access, understand, and benefit from the human genome, reported its financial results for the first quarter of its fiscal year 2023, which ended June 30, 2022.